Dyne’s Exon Skipper Delivers ‘Best Ever’ Functional Outcomes in Early DMD Study

Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the “best ever” for this treatment class, Stifel analysts said.